Economic evaluation of capecitabine use: As first line treatment in patients with advanced gastric carcinoma in Portugal;Avaliação económica da utilização de capecitabina: Como tratamento de primeira linha em doentes com carcinoma gástrico avançado em Portugal

Acta Medica Portuguesa

Volumn 22, Issue 6, 2009, Pages 827-832

  Macedo, Ana ^a   Pereira, Catarina ^b   Gonçalves, Joana ^a   Sousa, Conceição ^b  

^a Farmacologia Clínica e Ensaios Clínicos   (Portugal)

^b Roche Farmacêutica Química Lda ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL;

ADVANCED GASTRIC CARCINOMA; ANEMIA; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PORTUGAL; SENSITIVITY ANALYSIS; STOMACH DISEASE; STOMATITIS; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; COSTS AND COST ANALYSIS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PORTUGAL; STOMACH NEOPLASMS;

EID: 77149123962     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. BRANICKI FJ, GOTLEY DG: Gastric cancer. In Morris D, Kearsley J, Williams C, eds, Cancer: a comprehensive clinical guide. Harwood Academic Publishers 1998;165-9
2. YOSHIKAWA K, MARUYAMA K: Characteristics of gastric cancer invading to the proper muscle layer - with special reference to mortality and cause of death, Jpn J Clin Oncol 1985;15:499-503
3. LEE SS, LEE JL, RYU MH et al: Combination Chemotherapy with Capecitabine (X) and Cisplatine (P) as First Line Treatment in Advanced Gastric Cancer: Experience of 223 Patients with prognostic Factor Analysis. Jpn J Clin Oncol 2007;37:30-7
4. CUNNIGHAM D, JOST LM, PURKALNE G, OLIVEIRA J: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 2005;16(Suppl 1):i22-i23
5. BRITO RA, MEDGYESY D, ZUKOWSKI TH et al: Fluoropyrimidines: A Critical Evaluation. Oncology 1999;57(S1):2-8
6. European Medicines Agency: Relatório Público Europeu de Avaliação - XELODA (EMEA/H/C/316). London: 2008
7. KANG Y, KANG WK, SHIN DB et al: Randomized phase III trial of capecitabine/cisplatin vs. continuous infusion of 5-FU/ cisplatin as first-line therapy in patients with advanced gastric cancer: efficacy and safety results. J Clin Oncol 2006;24(18S)(June 20 Suppl):Abstract LBA4018
8. CUNNINGHAM D et al: Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatine with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. Clin Oncol 2006;24 (18S)(June 20 Suppl):Abstract LBA4017
9. FAN L, LIU WC, ZHANG YJ et al: Oral xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies. World J Gastroenterol 2005; 11(28):4300-4